Market Update: Amgen Inc (NASDAQ:AMGN) – FDA panel recommends approval for Amgen’s skin cancer immunotherapy

[Reuters] – Amgen Inc’s skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on . . . → Read More: Market Update: Amgen Inc (NASDAQ:AMGN) – FDA panel recommends approval for Amgen’s skin cancer immunotherapy Similar Articles: Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers